Company: PCRX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001396814-25-000041
Chunk: 223

Company: Pacira BioSciences, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 1A
Chunk 223
---
 price in response to various factors, including the following:

•the commercial success of EXPAREL, ZILRETTA and iovera°;

•our ability to execute on our business strategy;

•results of clinical trials of our products, product candidates or those of our competitors;

•changes or developments in laws or regulations applicable to our products or product candidates;

•introduction of competitive products or technologies;

Pacira BioSciences, Inc.  |  2024 Annual Report on Form 10-K  |  Page 59

•failure to meet or exceed financial projections we provide to the public;

•actual or anticipated variations in quarterly operating results;

•failure to meet or exceed the estimates and projections of the investment community;

•the perception of the pharmaceutical, biotechnological and medical device industry by the public, legislatures, regulators and the investment community;

•regulatory concerns or government actions;

•general economic and market conditions and overall fluctuations in U.S. equity markets and the impact of macroeconomic developments, such as general political, health and economic conditions, economic slowdowns, recessions, inflation, rising interest rates and the tightening of credit markets;

•increased interest rates and their generally negative effect on U.S. equity markets;

•developments concerning our sources of manufacturing supply;

•disputes or other developments relating to patents, intellectual property or other proprietary rights;

•additions or departures of key scientific or management personnel;

•the extent to which we acquire or invest in products, businesses and technologies;

•issuances of debt, equity or convertible securities;

•changes in the market valuations of similar companies; 

•evolving investor expectations and concerns regarding environmental, social and corporate governance issues; and

•the other factors described in this “Risk Factors” section.

In addition, the stock market in general, and the market for pharmaceutical, biotechnology and medical device companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. Fluctuations in our stock price could, among other things, adversely impact the trading price of our shares.

We do not intend to pay dividends on our common stock for the foreseeable future.

We have never declared or paid any dividends on our common stock. We currently intend to retain any future earnings to finance the future development and expansion of our business, and as such we do not